Daratumumab for multiple myeloma

被引：0
|
作者：
Croizier, Carolyne [1 ]
Bailly, Sebastien [1 ]
机构：
[1] CHU Clermont Ferrand, Serv Therapie Cellulaire & Hematol Clin, 1 Rue Lucie Aubrac, F-63100 Clermont Ferrand, France
来源：
BULLETIN DU CANCER | 2018年 / 105卷 / 11期
关键词：
Multiple myeloma; Daratumumab; Monoclonal antibody; Relapsed or refractory; DEXAMETHASONE; MONOTHERAPY; LENALIDOMIDE; INTERFERENCE; BORTEZOMIB; EFFICACY; OUTCOMES;
D O I：
10.1016/j.bulcan.2018.09.003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Daratumumab is a monoclonal antibody that targets CD38. It has on anti-tumor action on the myeloma cell and an immunomodulatory action. For relapsing and/or refractory myeloma patients, daratumumab is effective both alone and in combination and significantly improves progression-free survival. Daratumumab has been approved in 2016 in France for treatment of relapses or refractory multiple myeloma.
引用
收藏
页码：985 / 991
页数：7
相关论文
共 50 条
  • [1] Daratumumab in multiple myeloma
    Nooka, Ajay K.
    Kaufman, Jonathan L.
    Hofmeister, Craig C.
    Joseph, Nisha S.
    Heffner, Thomas L.
    Gupta, Vikas A.
    Sullivan, Harold C.
    Neish, Andrew S.
    Dhodapkar, Madhav, V
    Lonial, Sagar
    [J]. CANCER, 2019, 125 (14) : 2364 - 2382
  • [2] Daratumumab in multiple myeloma
    Rajkumar, S. Vincent
    [J]. LANCET, 2016, 387 (10027): : 1490 - 1492
  • [3] Daratumumab for the Treatment of Multiple Myeloma
    Plesner, Torben
    Krejcik, Jakub
    [J]. FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [4] Daratumumab: Beyond Multiple Myeloma
    Ejaz, Kiran
    Roback, John D.
    Stowell, Sean R.
    Sullivan, Harold C.
    [J]. TRANSFUSION MEDICINE REVIEWS, 2021, 35 (03) : 36 - 43
  • [5] Daratumumab for the treatment of multiple myeloma
    Touzeau, Cyrille
    Moreau, Philippe
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (07) : 887 - 893
  • [6] Daratumumab for the treatment of multiple myeloma
    Goldsmith, S. R.
    Foley, N.
    Schroeder, M. A.
    [J]. DRUGS OF TODAY, 2021, 57 (10) : 591 - 605
  • [7] Daratumumab for untreated multiple myeloma
    Stirrups, Robert
    [J]. LANCET ONCOLOGY, 2018, 19 (02): : E80 - E80
  • [8] The safety of daratumumab for the treatment of multiple myeloma
    Cejalvo, Maria J.
    Ribas, Paz
    de la Rubia, Javier
    [J]. EXPERT OPINION ON DRUG SAFETY, 2017, 16 (06) : 753 - 760
  • [9] Daratumumab improves survival in multiple myeloma
    Baker, Holly
    [J]. LANCET ONCOLOGY, 2016, 17 (11): : E480 - E480
  • [10] Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
    Dimopoulos, M. A.
    Oriol, A.
    Nahi, H.
    San-Miguel, J.
    Bahlis, N. J.
    Usmani, S. Z.
    Rabin, N.
    Orlowski, R. Z.
    Komarnicki, M.
    Suzuki, K.
    Plesner, T.
    Yoon, S. -S.
    Ben Yehuda, D.
    Richardson, P. G.
    Goldschmidt, H.
    Reece, D.
    Lisby, S.
    Khokhar, N. Z.
    O'Rourke, L.
    Chiu, C.
    Qin, X.
    Guckert, M.
    Ahmadi, T.
    Moreau, P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (14): : 1319 - 1331
12345